Use of recombinant human thrombopoietin (rHuTPO) after intensive chemotherapy

Patients with gynecologic malignancy were treated with high-dose carboplatin on day 1 of cycle 1 (gray columns, chemotherapy alone) and cycle 2 (blue columns, chemotherapy plus rHuTPO, administered daily). The administration of rHuTPO significantly increased the nadir platelet count, decreased the duration of thrombocytopenia, and reduced the need for platelet transfusion.